AMGEN Business Summary

Amgen Inc. (AMGN) is a global biopharmaceutical leader that generates revenue primarily through the discovery, development, and sale of innovative human therapeutics and a growing portfolio of biosimilars. The company’s business is organized across four primary therapeutic segments: General Medicine (including cardiovascular and bone health), Oncology, Inflammation, and Rare Disease. Following its $27.8 billion acquisition of Horizon Therapeutics, Amgen has significantly expanded its footprint in the rare disease market with high-growth assets like Tepezza and Krystexxa. As of February 2026, the company is navigating a strategic transition, leveraging a robust pipeline—headlined by the obesity candidate MariTide—to offset revenue erosion from biosimilar competition against legacy blockbusters like Prolia and Enbrel. Amgen competes directly with diversified pharmaceutical giants such as AbbVie, Eli Lilly, AstraZeneca, and Merck, maintaining a dominant position as one of the world’s largest independent biotechnology firms with 2025 revenues reaching $36.8 billion. Amgen was founded in 1980 by a group of scientists and investors, including venture capitalist William Bowes and the company’s first CEO, George Rathmann. The current leadership team is led by Chairman and CEO Robert A. Bradway, who joined the company in 2006 from Morgan Stanley and has served as CEO since 2012. Supporting the company’s technological evolution is Dr. David M. Reese, the inaugural Executive Vice President and Chief Technology Officer, who focuses on integrating artificial intelligence and human data into drug discovery. The research division is headed by Dr. James Bradner, EVP of R&D and Chief Scientific Officer, a former Novartis executive and Dana-Farber physician-scientist who joined in early 2024. The board of directors features prominent industry figures, including Lead Independent Director Robert Eckert (former CEO of Mattel) and Ellen Kullman (former CEO of DuPont), reflecting a governance structure with deep expertise in global manufacturing and scientific innovation.